JP2021514399A5 - - Google Patents

Info

Publication number
JP2021514399A5
JP2021514399A5 JP2020566547A JP2020566547A JP2021514399A5 JP 2021514399 A5 JP2021514399 A5 JP 2021514399A5 JP 2020566547 A JP2020566547 A JP 2020566547A JP 2020566547 A JP2020566547 A JP 2020566547A JP 2021514399 A5 JP2021514399 A5 JP 2021514399A5
Authority
JP
Japan
Prior art keywords
carbon atoms
phenyl
heteroaryl
membered
compound according
Prior art date
Application number
JP2020566547A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019164947A5 (https=
JP2021514399A (ja
JP7335275B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/018772 external-priority patent/WO2019164947A1/en
Publication of JP2021514399A publication Critical patent/JP2021514399A/ja
Publication of JPWO2019164947A5 publication Critical patent/JPWO2019164947A5/ja
Publication of JP2021514399A5 publication Critical patent/JP2021514399A5/ja
Application granted granted Critical
Publication of JP7335275B2 publication Critical patent/JP7335275B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020566547A 2018-02-20 2019-02-20 Egfrの阻害剤およびその使用法 Active JP7335275B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862632817P 2018-02-20 2018-02-20
US62/632,817 2018-02-20
US201862744085P 2018-10-10 2018-10-10
US62/744,085 2018-10-10
PCT/US2019/018772 WO2019164947A1 (en) 2018-02-20 2019-02-20 Inhibitors of egfr and methods of use thereof

Publications (4)

Publication Number Publication Date
JP2021514399A JP2021514399A (ja) 2021-06-10
JPWO2019164947A5 JPWO2019164947A5 (https=) 2022-02-25
JP2021514399A5 true JP2021514399A5 (https=) 2022-02-25
JP7335275B2 JP7335275B2 (ja) 2023-08-29

Family

ID=67687389

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020566547A Active JP7335275B2 (ja) 2018-02-20 2019-02-20 Egfrの阻害剤およびその使用法

Country Status (6)

Country Link
US (1) US11584746B2 (https=)
EP (1) EP3755689B1 (https=)
JP (1) JP7335275B2 (https=)
AU (1) AU2019225805A1 (https=)
CA (1) CA3087716A1 (https=)
WO (1) WO2019164947A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021514011A (ja) * 2018-02-20 2021-06-03 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Egfr阻害剤の組合せ医薬製剤およびその使用法
CA3087288A1 (en) * 2018-02-20 2019-08-29 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
AU2019225799A1 (en) * 2018-02-20 2020-07-09 Dana-Farber Cancer Institute, Inc. Pharmaceutical combinations of EGFR inhibitors and methods of use thereof
WO2024168152A1 (en) * 2023-02-08 2024-08-15 The Research Foundation For The State University Of New York Benzodiazepinone-derived inhibitors of egfr and her2

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070105835A1 (en) 2005-11-07 2007-05-10 Kazantsev Aleksey G Compositions and methods for modulating poly(ADP-ribose) polymerase activity
US20110028458A1 (en) * 2008-04-11 2011-02-03 Thallion Pharmaceuticals Inc. Inhibition of cell migration by a farnesylated dibenzodiazepinone
CA2746220A1 (en) 2008-12-08 2010-07-08 Vm Pharma Llc Compositions of protein receptor tyrosine kinase inhibitors
EP2379559B1 (en) 2009-01-06 2017-10-25 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
US9156233B2 (en) 2012-10-22 2015-10-13 Us Floors, Inc. Engineered waterproof flooring and wall covering planks
WO2014160430A1 (en) 2013-03-13 2014-10-02 Georgetown University Small molecule lrrk2 and erk5 inhibitors
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
US11155556B2 (en) 2016-04-07 2021-10-26 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders
TW201834651A (zh) 2016-12-22 2018-10-01 瑞士商赫孚孟拉羅股份公司 化合物
WO2018220149A1 (en) 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Compounds
CA3087288A1 (en) 2018-02-20 2019-08-29 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
JP2021514011A (ja) 2018-02-20 2021-06-03 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Egfr阻害剤の組合せ医薬製剤およびその使用法
KR102277626B1 (ko) 2018-08-16 2021-07-15 한국화학연구원 이소인돌린-1온 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물

Similar Documents

Publication Publication Date Title
JP2021514400A5 (https=)
RU2495044C2 (ru) Ингибиторы активности протеинтирозинкиназы
RU2500680C2 (ru) Новые замещенные пиридин-2-оны и пиридазин-3-оны
JP2021523221A5 (https=)
JP2010504346A5 (https=)
JP2021514399A5 (https=)
RU2405774C9 (ru) Гетероциклические ингибиторы аспартилпротеазы
RU2328486C2 (ru) Производные 2-пиридона в качестве ингибиторов нейтрофильной эластазы
RU2350605C2 (ru) Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ
JP2008535903A5 (https=)
AR056327A1 (es) Compuestos de nucleosidos para el tratamiento de infecciones virales
JP2008535902A5 (https=)
JPWO2019155399A5 (https=)
PE20212253A1 (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd)
JP2011219498A5 (https=)
JPWO2020243415A5 (https=)
JP2019519586A5 (https=)
JP2010504347A5 (https=)
EA201990902A1 (ru) Ингибиторы тирозинкиназы брутона
JP2021535213A5 (https=)
CN111601797A (zh) 苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用
RU2009119181A (ru) Гетероциклические соединения и их применение в качестве ингибиторов гликогенсинтаза-киназы-3
JP2021514011A5 (https=)
RU2008107733A (ru) Ингибиторы gsk-3
JP2007517007A5 (https=)